Hydreight Announces Normal Course Issuer Bid
Rhea-AI Summary
Hydreight (OTCQB: HYDTF; TSXV: NURS) announced a normal course issuer bid to repurchase up to 4,951,189 common shares, representing ~9.27% of issued shares and ~10.0% of the public float. The Bid runs from March 12, 2026 to March 11, 2027.
Purchases will be made on the Exchange at prevailing market prices through Research Capital Corporation and funded from existing working capital. The company said purchases aim to facilitate an orderly market and could be used if shares trade below perceived underlying value.
AI-generated analysis. Not financial advice.
Positive
- Authorized repurchase of 4,951,189 shares (~9.27%)
- Buyback covers up to 10.0% of public float
- Program runs from March 12, 2026 to March 11, 2027
Negative
- Buyback funded from existing working capital
- Purchases at the prevailing market price could increase cash outflow
News Market Reaction – HYDTF
On the day this news was published, HYDTF gained 2.56%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
HYDTF slipped -1.52% while key peers were mostly flat or down: MDRX -5.33%, VHIBF -3.04%, and others at 0%. No momentum-clustered sector move was detected.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Revenue guidance & financing | Positive | +6.4% | Issued 2026 revenue and EBITDA guidance plus a $15M bought-deal financing. |
| Dec 31 | New product launch | Positive | +10.2% | Entered at-home STI testing market with exclusive deal and ~50,000 pre-orders. |
| Dec 18 | Operational milestone | Positive | +2.5% | Surpassed 1.3M product orders and exceeded 2025 operational targets. |
| Dec 02 | Corporate update | Positive | +26.2% | Highlighted strong Q3 momentum, VSDHOne growth, and 2026 strategic priorities. |
| Nov 26 | Earnings results | Positive | -9.8% | Reported 132% YoY revenue growth and fourth consecutive profitable quarter. |
Positive operational and guidance updates have usually been met with positive price reactions, with one notable divergence on strong quarterly results.
Over the past several months, Hydreight has reported rapid growth and expanding initiatives. Q3 2025 results showed strong revenue growth and profitability on Nov 26 and Dec 2, followed by milestones like surpassing 1.3M product orders on Dec 18. The company then entered the at-home STI testing market with about 50,000 pre-orders on Dec 31, and issued fiscal 2026 revenue guidance of roughly $150M on Feb 2. Today’s buyback announcement follows this trajectory of scaling operations and capital deployment.
Market Pulse Summary
This announcement introduced a normal course issuer bid authorizing repurchases of up to 4,951,189 shares, about 9.27% of outstanding stock and 10.0% of the 49,511,894-share public float, funded from existing working capital. It follows a series of growth-oriented updates involving revenue expansion, new product lines, and rising order volumes. Investors may watch actual buyback activity, future guidance, and subsequent operational metrics to gauge how capital allocation supports the company’s growth plans.
Key Terms
normal course issuer bid financial
public float financial
tsx venture exchange regulatory
management information circular regulatory
AI-generated analysis. Not financial advice.
The Bid will be conducted in accordance with applicable securities laws and the policies of the Exchange. Purchases will be made on the open market through the facilities of the Exchange. The price which the Company will pay for any shares purchased by it will be the prevailing market price of such common shares on the Exchange at the time of such purchase. The purchase of the common shares under the Bid is being funded from existing working capital.
In accordance with Exchange policies, the Company will include a summary of the Bid in the management information circular to be mailed to shareholders of the Company in respect of its next meeting of shareholders.
The Company believes that purchases of its common shares pursuant to the Bid may contribute to the facilitation of an orderly market and is in the best interests of the Company and its shareholders. In the event that the Company believes that its common shares begin trading in a price range that does not adequately reflect their underlying value based on the Company's business prospects, growth and financial position, the Company may purchase common shares pursuant to the Bid.
Shane Madden, Chief Executive Officer of Hydreight, commented:
"Hydreight has continued to demonstrate strong operational momentum as we scale our digital health infrastructure platform across
On behalf of the Board of Directors
Shane Madden
Director and Chief Executive Officer
Hydreight Technologies Inc.
Hydreight Technologies Inc Ranked Number 56 Fastest-Growing Company in
Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
About Hydreight Technologies Inc.
Hydreight Technologies Inc is building one of the largest mobile clinic networks in
About VSDHOne - Direct to Consumer Platform
Developed in partnership with Victory Square Technologies (CSE: VST) (OTC: VSQTF) (FWB: 6F6), Hydreight Technologies launched the VSDHOne (Read as VSDH-One) platform. VSDHOne simplifies the entry challenges for companies and medi-spa businesses to enter the online healthcare space compliantly. This platform will help all businesses to launch a direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy, hair loss, skincare, sexual health and more. Hydreight invested in technology, legal and infrastructure to launch this platform. The VSDHOne platform offers a complete, and modular end-to-end solution for businesses looking to launch direct-to-consumer healthcare brands. From compliance and telemedicine technology to nationwide doctor and pharmacy networks, VSDHOne provides all the tools needed for a seamless entry into the online healthcare space. The platform is designed to significantly reduce the time and costs associated with launching such services, making it possible for businesses to go live in days instead of months.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements, including statements regarding the Bid. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward looking statements, oral or written, made by itself or on its behalf, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hydreight-announces-normal-course-issuer-bid-302707912.html
SOURCE Hydreight Technologies Inc.